Aims: The Observational Study of Severe Osteoporosis (OSSO) is a 12-month, European, prospective study aiming to assess the changes in Health Related Quality of Life (HRQoL) of women with osteoporosis (OP) and an inadequate clinical response to antiresorptive (AR) medications.
Methods: In Greece, 263 of 271 (97%) patients (pts) with severe OP met the inclusion criteria. The study population was assigned to1of 2 groups according to one or more of the following criteria: a) Pts who sustained a new clinical fragility fracture, despite an AR treatment at least 12 months prior to this fracture (Group A); b) Pts who discontinued AR therapy because of non compliance and/or side effects (Group B). After applying a Bonferroni correction, p-values less than 0.003 were considered statistically significant.
Results: Group A consisted of 143 pts (54.4%) aged 71.4 yrs with BMI 27.4 kg/m2. T-score was −3.1 both at the lumbar spine vertebra (LSV) and femoral neck (FN). Group B consisted of 120 pts (45.6%) with aged 64.7 yrs and BMI of 26.4 with T-score −3.1 at LSV and −2.6 at FN. 63% and 42% from groups A and B respectively had ≥1 fragility fractures (excluding the index fracture that made them eligible for the study) <40 yrs. In group A calcitonin (CAL) was the most common OP treatment taken at study entry (47.6%) followed by bisphosphonates (BPs) (39.2%=Aln+Ris+Eti+Pam=(34+16+5+1)/143) while for group B BPs was 40.8% and CAL was 15.0%. Alendronate was the most frequently discontinued qualifying AR drug (38.2%) due to non compliance. The 2 groups were similar with respect to age at menopause (46.5 yrs), number of live born children, hearing (19.8%) and sight problems (49.0%). Differences were observed between groups A and B in yrs past menopause (25.0 vs 17.9), current (18.9% vs 7.5%) and past (25.9% vs 11.7%) use of glucocorticoids and women who had falls in previous year (51.1% vs 31.7%).
Conclusions: Despite the differences observed in baseline characteristics between the 2 groups of postmenopausal women with inadequate response to AR therapy according to the previously mentioned criteria they both had numerous risk factors for a next fracture.
01 - 05 Apr 2006
European Society of Endocrinology